https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/gene-therapy-trial-patients-fanconi-anaemia-open-gosh/
Gene therapy trial for patients with Fanconi anaemia to open at GOSH
22 Mar 2016, 5:24 p.m.
A clinical trial is to open at Great Ormond Street Hospital (GOSH) that will test the use of gene therapy during transplantation for the treatment of young people with Fanconi anaemia. The trial will be led by Dr Claire Booth, Dr Phil Ancliff and Professor Adrian Thrasher – who is the Gene, stem and cellular therapies Theme Lead at the Great Ormond Street BRC.
Fanconi anaemia is a life-limiting, inherited haematological disorder which causes bone marrow failure in childhood as well as other serious complications. Children can be treated with a bone marrow transplant but the success of this procedure depends on finding a well matched donor for the patient.
The clinical trial due to open at GOSH in the coming months will assess whether gene therapy could offer hope to children lacking a suitable donor for transplant.
Researchers will make use of the BRC-funded GMP facility to genetically modify the patient’s own stem cells during the trial.
Celebrating research that transforms lives
The 2025 NIHR GOSH BRC Showcase recently celebrated some incredible progress made in paediatric research.
Landmark gene therapy study shows safety for children
Results from the largest cohort of children who received a gene therapy for a rare immunodeficiency condition have shown the long-term safety and efficacy of the curative treatment.
New study pinpoints why some transplanted kidneys are rejected
Researchers at University College London (UCL), the Wellcome Sanger Institute and the University of Cambridge combined technology that determines the genetic or RNA sequence of individual cells with powerful 3D imaging to look at lymphatic vessels
Scientists discover clues to help children with rare muscle disease
New ground-breaking research by experts at Great Ormond Street Hospital (GOSH) and University College London (UCL) has led to an exciting discovery that could help children with the rare muscle disease, juvenile dermatomyositis (JDM).